Abstract
INTRODUCTION:
Neuromyelitis Optica (NMO) is an inflammatory syndrome of the central nervous system, different from multiple sclerosis, that is associated with aquaporin-4 IgG antibodies (AQP4-IgG). The new nomenclature defines a unified term of Neuromyelitis Optica Spectrum Disorder (NMOSD), seropositive or seronegative according to the AQP4-IgG positivity.
OBJECTIVES:
Demographic, clinical, imaging and cerebrospinal fluid (CSF) cytochemistry characterization of patients diagnosed with NMOSD at the Hospital Universitario San Ignacio (HUSI), Bogotá, Colombia, during 2006-2017.
METHODS:
A descriptive observational longitudinal study of patients diagnosed with NMO according to the International consensus diagnostic criteria for neuromyelitis optica spectrum disorders 2015 evaluated in HUSI during 2006-2017. An analysis of quantitative variables was performed with mean, standard deviation, median and interquartile range (IQR), and of qualitative variables with absolute numbers and percentages. A Wilcoxon sign-rank sum test was performed for paired data to evaluate the correlation between visual acuity (VA) and EDSS disability scale at admission and discharge after treatment.
RESULTS:
Data was collected for 37 patients. The mean age was 42 years-old. The form of presentation was optic neuritis (ON) in 81.1% of the cases. In patients who presented as ON, it was typical in 21.6%, atypical in 43.2% and bilateral in 18.9% of them. An average of 4.6 plasmapheresis (PPH) were performed; at discharge 45.9% presented a visual acuity (VA) lower than 20/800. The mean Expanded Disability Status Scale (EDSS) on admission was 2.8 (SD 1,4) and 2.2 (SD: 1,4). at discharge.
CONCLUSION:
Colombian NMOSD patients have shown an increasingly frequent phenotype variability Including a higher proportion of patients with bilateral optic neuritis, smaller number of patients with oligoclonal bands pattern II and with typical lesions of multiple sclerosis (MS) in MRI with seropositive NMO and a greater number of cases debuting with partial segment partial myelitis.
References
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-89.
Wingerchuk DM, Lennon VA, Pittock SJ,Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology, 2006;66(10):1485-9.
Reyes IMA, Navas Granados AV, Ramírez SF. Spectrum of optic neuromyelitis in Colombia, first characterization clinical and radiological in three centers of Bogotá. Acta Neurol Colomb. 2016;32(3):190-202.
Melamed E, Levy M, Waters PJ, et al. Update on bio-markers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm.2015;2(4):e134.
Mata S, Lolli F. Neuromyelitis optica: an update. J Neurol Sci. 2011;303(1-2):13-21.
Lennon PVA, Wingerchuk DM, Kryzer TJ. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12.
Drori T, Chapman J. Diagnosis and classification of neuromyelitis optica (Devic's Syndrome). Autoimmun Revi 2014;13:531-3.
Pereira WL, Reiche EM, Kallaur AP, Kaimen-Maciel DR. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review. J Neurol Sci. 2015;355(1-2):7-17
Etemadifar M, Nasr Z, Khalili B. Epidemiology of neuromyelitis optica in the world: A systematic review and meta-analysis. Mult Scler Int.2015;2015:174720.
Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76(18):1589-95.
Flanagan E, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775-83.
Cabre P, Gonzalez-Quevedo A, Lannuzeletal A. Descriptive epidemiology of neuromyelitis optica in the Caribbean basin. Rev Neurol. 2009;165-(8-9):676-83.
Jacob A, Panicker J, Lythgoe D, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol. 2013;260(8):2134-7.
Cabrera-Gómez JA, Kurtzke JF, Gonzalez-Quevedo A, Lara-Rodriguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol, 2009:256(1),35-44.
Rivera JF, Kurtzke JF, Booth VJ, Corona VT. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol. 2008; 255(5):710-5.
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473-7.
Varrin-Doyer M, Spencer CM, Schulze-Topphoff U et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012;72:53-64.
Sellner J, Hemmer B, Muhlau M. The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun 2010;34(4):371-9.
Bennett JL, Lam C, Kalluri SR et al. Intrathecal pathogenic anti- aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66(5):617-29.
Popescu BF, Lennon VA, Parisi JE et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011; 76(14):1229-37.
Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica. J Neurol 2004; 251(1):47-52.
Verkman AS. Aquaporins in clinical medicine. Annu Rev Med 2012;63:303-16.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6(9):805-15.
Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. JNeuroinflammation. 2012;Jan 19;9:14.
Jarius S, Paul F, Franciotta D, De Seze J, Münch C, Salvetti M, et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin- 4 antibody positive cases and a review of the literature. Mult Scler. 2012;18(8):1135-43.
Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler a Population of Colombian Patients with Neuromyelitis Optica - Spectrum Disorder J. 2015; 21(7):845-53.
Matiello M, Lennon VS, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70(23):2197-200.
Sellner J, Hemmer B, Mühlau M. The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun. 2010;34(4):371-9.
Jarius S, Wildemann B.The history of neuromyelitis optica. JNeuroinflammation 2013; Jan 15;10:8.
Kira J-I. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003;2(2):117-27.
Jacob A, Mckeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013;84(8):922-30.
Di Pauli F, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin. Immunol. 2011;138(3):247-54.
Akmar-Demir G, Tuzun E, Waters P, et al. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol 2011;258(3):464-70.
Wang H, Dai Y, Qiu W,, et al. HLA-DPB1*0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in Southern Han Chinese. J Neuroimmunol. 2011;233(1-2): 181-4.
Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59(3):566-9.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.